Proof that Sn-protoporphyrin inhibits the enzymatic catabolism of heme in vivo. Suppression of 14CO generation from radiolabeled endogenous and exogenous heme sources by unknown
BriefDefinitive Report
PROOF THAT Sn-PROTOPORPHYRIN INHIBITS THE
ENZYMATIC CATABOLISM OF HEME IN VIVO
Suppression of"CO Generation from Radiolabeled Endogenous and
Exogenous Heme Sources
BY STEPHEN A. LANDAW, SHIGERU SASSA,* GEORGE S. DRUMMOND,*
AND ATTALLAH KAPPAS*
From the Veterans Administration Medical Center, Syracuse, New York 13120; and
*The Rockefeller University Hospital, New York 10021
An extensive series of studies by Kappas and Drummond (see review in
reference 1) has demonstrated that the synthetic heme analogue, tin(Sn)-proto-
porphyrin (SnPP) acts as a potent competitive inhibitor of heme oxygenase (2-
4), and can suppress hyperbilirubinemia in experimentally induced and naturally
occurringforms ofjaundice in animalsandman (2, 3, 5, 6) . SnPP also significantly
diminishes the output of biliary bilirubin derived from endogenous and exoge-
nous heme sources (7), does not affect the metabolic disposition of preformed
bilirubin (7), and elicits a marked biliary excretion of untransformed heme in
bile duct-cannulated animals (8).
In the process ofheme degradation catalyzed by the enzyme heme oxygenase,
one mole of carbon dioxide (CO) is generated for each mole of bile pigment
produced (9, 10) . Thus the findings reported above would support the expecta-
tion that SnPP would diminish the generation of CO from the catabolism of
various heme moieties in vivo . We have examined this question by studying the
generation of "CO from radiolabeled heme sources in the intact animal . The
use of specifically labeled heme is crucial in answering this question since CO
may be generated from sources other than heme (11-14). The results of these
experiments prove conclusively that SnPP markedly inhibits the enzymatic oxi-
dation in vivo ofheme from both endogenous and exogenous sources.
Materials and Methods
Animals used were 300-400 g Sprague-Dawley rats obtained from Taconic Farms,
Germantown, NY. SnPP was provided by Porphyrin Products, Logan, UT . The labeled
precursor 6-aminolevulinic acid (5-['4C]ALA) (Sp act, 49 mCi/mM) was obtained from
New England Nuclear, Boston,MA . Labeled ["C]hemin (Sp act, 3.0 X 10' dpm/mg) was
prepared in rats by methods previously described (9) . Before injection into animals, 1 .0
mg of the crystallized hemin was dissolved in 1 ml of alkalinized rat plasma, and injected
intravenously within 15 min of preparation . SnPP was dissolved in a small amount of 0.2
N NaOH, a 3.5-fold greater volume of 0.9% NaCl was added, and pH was adjusted to
This work was supported in part by the Veterans Administration, grant ES-01055 from the
U.S . Public Health Service, the Dyson Foundation, theRenfield Foundation,andtheOgden Corpor-
ation .
journalof Experimental Medicine " Volume 165
￿
April 1987
￿
1195-1200
￿
11951196
￿
LANDAW ET AL .
￿
BRIEF DEFINITIVE REPORT
FIGURE . 1 .
￿
Semilogarithmic plot of the ex-
cretion rate of "CO (dpm/h, ordinate) vs .
time after injection of 5-["C]ALA (h, ab-
scissa) . To facilitate comparisons within this
figure and with the results shown in Fig . 2,
all "CO excretion data for control (saline-
injected) animals were normalized such that
total 14CO excretion in the period 0-12 h
afterALA injection was set at 100,000 dpm .
For experimental animals, data were nor-
malized for a dose- of ALA that yielded
100,000 dpm in the first 12 h forthecontrol
animal run on the same date . The shaded
area denotes the total range of normalized
values for four control animals injected with
saline 1 h before 5-["C]ALA . Results from
four animals injected with SnPP (50
,umol/kg body weight) 1 h before injection
of 5-["C]ALA are shown (often circles, mean
± SD) . Note that the inhibition of "CO
excretion produced by SnPP was rapid, and
the effect appeared to last ^-8-9 h .
7.5 by dropwise addition of 0.5 N HCI (6) . The compound was injected subcutaneously
in a dose of 50 lamol/kg body weight at various time periods before or after injection of
the labeled materials . Equal volumes of saline were injected by the same route for the
control animals .
The degradation of labeled heme was followed by quantitation of the excretion of "C-
labeled carbon monoxide ("CO), using previously described methods (9) . Immediately
after injection of labeled material, rats were placed in flow-through metabolic chambers
provided with food, water, and bedding. Labeled "CO was then collected continuously
over the next 24-30 h, and expressed asdpm of"CO excreted over various time intervals .
Student's t test was used to determine the statistical significance of results .
Results
Effect ofSnPP on "CO Generation after 5-[ 14C]ALA Administration .
￿
In the rat,
5-[ 14C]ALA is incorporated almost exclusively into nonerythropoietic hernes (15,
16), labeling bilirubin and CO to very high activity within minutes of injection
(17, 18) . The peak of "CO excretion occurs early, about 2-3 h after injection
of 5-[14C]ALA, and is followed by a rapid exponential decline (Fig . 1), with 3-
4% of the injected dose appearing as "CO within the first 12 h after injection
(Table 1) .
When 50 Amol/kg body weight of SnPP was injected 1 h before injection of
5-[ 14C]ALA, there was a prompt reduction in "CO excretion, lasting ^-8-9 h
(Fig . 1) . The peak of "CO excretion at 2-3 h was virtually abolished, and total
14C0 excretion in the first 12 h was reduced by ^-60% (p < 0.005, Table I) .
Thereafter, "CO excretion was identical to the control animals (Table I and
Fig . 1) .
In separate experiments, SnPP or saline was injected subcutaneously into four
rats 11 h after 5-[ 14C]ALA ; "CO excretion was monitored for the entire time
period 0-35 h after 5-[ 14C]ALA injection . When compared with controls, 14CO
excretion was reduced 48% for the time period for 12-24 h after injection of 5-
[ 14C]ALA corresponding to 1-13 h after injection of SnPP (Fig . 2) . 14CO
excretion rates were similar to controls before injection of SnPP (0-10 h after*p <0.005 .
xp<0.01 .
1p >0.05 .
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TABLE I
Effect ofSnPP on Cumulative Excretion of"CO afterHemin or ALA "CO Excretion
(Percent ofInjected Dose)
FIGURE 2. Semilogarithmic plot of excretion
rate of "COvs . time after injectionof 5-[14C]ALA
details similar to those in Fig. 1 . A single animal
injected with saline 11 h after injection of labeled
ALA is shown with the solid circles, while results
from three animals injected with SnPP 11 h after
injection of labeled ALA are shown as the open
circles (meanf SD). The shaded area represents
thesame values of theshaded area in Fig. 1 . Data
points in theexperimental groups were normalized
to 100,000 dpm during the control period (0-12
h after ALA) . Inhibition of "CO excretion pro-
ducedby SnPP began immediately, with the effect
lasting about 14-20 h.
5-[
14C]ALA), and were again similar to controls by ^-20 h after injections of
SnPP.
Effect ofSnPP on ' 4Ç0 Excretion after [' 4C]Hemin Administration.
￿
[14C]Hemin
prepared in vivo from 2-[ 14C]glycine (9) was injected intravenously in alkalinized
plasma to eight rats, divided into four pairs . From each pair, one rat was injected
with SnPP and the other with saline, to control for day-to-day variability in the
preparation of solubilized hemin . As with 5-[14C]ALA, excretion of labeled
bilirubin and CO after [ 14C]hemin is rapid (9), with peak excretion occurring 2-
3 h after injection, 5-22% of the injected dose appearing as 14CO within 12 h
after injection (Table I) .
When 50 Amol/kg body weight SnPP was injected 1 h before [14C]hemin,
there was a 46% reduction (p < 0.01, Table I) in 14CO excretion over the
ensuing 12 h . In the period 12-24 h after injection, there was a sustained and
Compound injected Control
group
0-12 h
SnPP
group
Percent
change
Control
group
12-24 h
SnPP
group
Percent
change
5-[14C]ALA 3.10 0.90 -71 0.34 0.41 +20
3.92 1 .37 -65 0.57 0.68 +19
3.35 1 .45 -57 0.64 0.63 -2
2.79 1 .36 -51 0.64 0.56 -12
Mean 3.29 1 .27 -61* 0.55 0.57 +6
["C]Hemin 4.63 1 .92 -59 0.99 0.62 -37
6.56 2.23 -66 1 .03 0.74 -28
20.04 13.59 -32 3.42 2.41 -30
21 .70 16.30 -25 9.21 5.63 -39
Mean 13.23 8.51 -46x 3.66 2.35 -3411198
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consistent reduction in "CO excretion in SnPP-treated animals (mean decline,
34%), but this value did not reach statistical significance (p > 0.05, Table 1).
Discussion
Drummond and Kappas proposed that (2) the mechanism of suppression of
hyperbilirubinemia by SnPP involves a potent and sustained competitive inhibi-
tion of heme oxygenase by this synthetic metalloporphyrin . Such a mechanism
would presuppose a concurrent diminution of production of bilirubin as well as
of CO after treatment of animals with this synthetic heme analogue. Suppression
of bilirubin production by SnPP has been confirmed (7). Milleville et al . (19, 20)
and more recently Posselt et al. (21), using mature mouse and newborn rat
models, respectively, but without using radiolabeled heme, have reported that
SnPP reduces CO generation from endogenous heme and from heme derived
from hematomas as well as exogenous sources, by ^-18-30% and 35-56%,
respectively . The variable time periods between injection of SnPP and its effects
on CO production probably account for the differences in effects noted in these
experiments.
The results of the present study, using highly specific techniques for quanti-
tating "CO generation from the catabolism of radiolabeled heme moieties,
conclusively establish that SnPP suppresses CO generationand does so at rates
comparable to those by which biliary bile pigment output is diminished by SnPP
(7). The experiments described here indicate that, when 5-["C]ALA is used as a
heme precursor, the suppressive effect of SnPP on "CO excretion lasts about
8-20 h, whether the metalloporphyrin is given 1 h before (Fig. 1) or 11 h after
(Fig. 2) the 5-[` 4C]ALA. These observations thus suggest a duration of action in
vivo of a single dose of SnPP in the range of about 12 h, despite the prolonged
retention (in part in nonenzymatic tissue sites as previously suggested [22]) of
the compound in the liver and other organs. Our findings also suggest that
degradation of the heme moieties of both rapid and relatively slowly turning
over hemeproteins in the liver is suppressed by SnPP.
Kappas et al. (8) have reported that the administration of SnPP leads to a
marked increase in the biliary excretion of untransformed heme after the
injection of both hemin and heat-damaged red blood cells, and that this excretion
of heme quantitatively accounts for much of the concurrent decline seen in the
output of biliary bilirubin . Similar results have recently been reported by Hintz
et al. (23). The effect of SnPP on heme excretion after the administration of
heat-damaged red blood cells, though significant, was less than that seen after
injection of hemin, and was more variable in individual animals (7). This suggests
that SnPP can inhibit to some extent extrahepatic heme degradation in vivo, as
well as hepatic heme catabolism. The in vivo effects of SnPP in the liver and in
extrahepatic tissues such as the spleen, however, are probably not equal, since
the findings of Simionatto et al. (7), using heat-damaged erythrocytes, could be
explained in part by the transport of unmetabolized, excess heme or hemoglobin
from splenic to hepatic sites for degradation. Thus, significant inhibition of heme
catabolism by SnPP may be primarily manifest on liver heme moieties or in
circumstances when the organism is presented with a substantial excess of heme,LANDAW ET AL .
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as in the immediate postnatal period in the newborn or when erythrocyte
destruction is marked and sustained .
Summary
Sn-protoporphyrin (SnPP) suppresses generation of "Co from hepatic heme
labeled with S-aminolevulinic acid (5-[14C]ALA) or from infused [14C]hemin in
rats . SnPP administered 1 h before administration of 5-[ 14C]ALA virtually
abolished the peak output of 14CO occurring 2-3 h after injection of this heme
precursor, and during the succeeding 12 h reduced 14CO excretion by -61
compared with controls . When [14C]hemin was infused, SnPP diminished 14CO
excretion by -50% . These findings, derived from experiments using radiolabeled
endogenous and exogenous heme sources, establish conclusively that the syn-
thetic metalloporphyrin SnPP inhibits the oxidative degradation of heme in the
intact animal .
Receivedfor publication 17 December 1986 .
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